Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
OCS
Upturn stock ratingUpturn stock rating

Oculis Holding AG Ordinary shares (OCS)

Upturn stock ratingUpturn stock rating
$19
Last Close (24-hour delay)
Profit since last BUY-2.56%
upturn advisory
WEAK BUY
BUY since 25 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/03/2025: OCS (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $38.54

1 Year Target Price $38.54

Analysts Price Target For last 52 week
$38.54 Target price
52w Low $10.79
Current$19
52w High $23.08

Analysis of Past Performance

Type Stock
Historic Profit 27.51%
Avg. Invested days 44
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/03/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 969.64M USD
Price to earnings Ratio -
1Y Target Price 38.54
Price to earnings Ratio -
1Y Target Price 38.54
Volume (30-day avg) 7
Beta 0.14
52 Weeks Range 10.79 - 23.08
Updated Date 07/4/2025
52 Weeks Range 10.79 - 23.08
Updated Date 07/4/2025
Dividends yield (FY) -
Basic EPS (TTM) -3

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -7008.42%

Management Effectiveness

Return on Assets (TTM) -32.13%
Return on Equity (TTM) -85.16%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 741248705
Price to Sales(TTM) 1294.58
Enterprise Value 741248705
Price to Sales(TTM) 1294.58
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.47
Shares Outstanding 51033700
Shares Floating 41222545
Shares Outstanding 51033700
Shares Floating 41222545
Percent Insiders 6.35
Percent Institutions 30.98

ai summary icon Upturn AI SWOT

Oculis Holding AG Ordinary shares

stock logo

Company Overview

overview logo History and Background

Oculis Holding AG is a biopharmaceutical company dedicated to developing transformative topical ophthalmic treatments. Founded in 2003 as NeuroMedix, it was later renamed to Oculis and has evolved to focus on addressing unmet needs in ophthalmology. Key milestones include clinical trials for various ophthalmic conditions and partnering with investors to take the company public in 2024 via SPAC.

business area logo Core Business Areas

  • OCU-CLEN (formerly NMX-003): OCU-CLEN is a once-daily disease modifying treatment candidate for Glaucoma, that provides local anti-inflammatory and anti-fibrotic activities.
  • OCU-NOV (formerly NMX-002): OCU-NOV is a novel topical ophthalmic formulation of neurotrophic factor designed to treat neurotrophic keratitis (NK).
  • OCU-PLAS (formerly NMX-001): OCU-PLAS is a novel, preservative-free topical treatment candidate for Dry Eye Disease (DED) designed to address signs and symptoms of DED.

leadership logo Leadership and Structure

The leadership team is comprised of Riad Sherif, MD, CEO, and other executives with experience in ophthalmology and pharmaceutical development. The organizational structure includes research, clinical development, regulatory affairs, and commercial teams.

Top Products and Market Share

overview logo Key Offerings

  • OCU-PLAS: A Dry Eye Disease (DED) treatment candidate. Currently in clinical trials. Market share is not yet applicable as the product is not yet approved. Competitors include Restasis (AGN), Xiidra (NOVN), and Miebo (BXQ).
  • OCU-NOV: A neurotrophic keratitis (NK) treatment candidate. Currently in clinical trials. Market share is not yet applicable as the product is not yet approved. Competitors include Oxervate (Dompu00e9 farmaceutici S.p.A.).
  • OCU-CLEN: A Glaucoma treatment candidate. Currently in clinical trials. Market share is not yet applicable as the product is not yet approved. Competitors include various IOP-lowering drops (e.g., latanoprost) and surgical interventions.

Market Dynamics

industry overview logo Industry Overview

The ophthalmic pharmaceutical market is experiencing growth due to an aging population, increased prevalence of eye diseases, and advancements in treatment options. It is highly competitive, with both large pharmaceutical companies and smaller biotech firms vying for market share.

Positioning

Oculis Holding AG is positioned as an innovative company focused on developing topical ophthalmic treatments to address unmet needs. Its competitive advantage lies in its novel formulations and focus on treating underserved patient populations.

Total Addressable Market (TAM)

The TAM for Dry Eye Disease is estimated to be several billion dollars annually. The TAM for Neurotrophic Keratitis is smaller but still significant. Oculis is positioned to potentially capture a portion of this market with its innovative products.

Upturn SWOT Analysis

Strengths

  • Novel topical ophthalmic formulations
  • Focus on unmet needs in ophthalmology
  • Experienced leadership team
  • Strong intellectual property portfolio

Weaknesses

  • Reliance on successful clinical trial outcomes
  • No currently marketed products
  • Limited financial resources compared to larger pharmaceutical companies
  • Regulatory risks associated with drug development

Opportunities

  • Positive clinical trial results
  • Regulatory approval of its drug candidates
  • Strategic partnerships with larger pharmaceutical companies
  • Expansion into new ophthalmic indications

Threats

  • Failure to achieve positive clinical trial results
  • Regulatory setbacks or delays
  • Competition from existing treatments
  • Patent challenges
  • Changes in reimbursement policies

Competitors and Market Share

competitor logo Key Competitors

  • AGN
  • NOVN
  • BXQ

Competitive Landscape

Oculis Holding AG faces competition from established pharmaceutical companies with marketed ophthalmic products. Oculis's competitive advantage lies in its novel formulations and focus on unmet needs.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is primarily focused on clinical development and fundraising.

Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and commercial launch of its ophthalmic treatments. Analyst estimates vary but are generally positive.

Recent Initiatives: Recent initiatives include advancing its lead drug candidates through clinical trials and securing financing for further development.

Summary

Oculis Holding AG is a biopharmaceutical company with an experienced leadership team that has been advancing through clinical trials for ophthalmic treatments to address unmet needs. There are no current marketed products, so the future is highly dependent on successful clinical trial outcomes. Oculis's advantage is their novel topical ophthalmic formulations, but they face stiff competition. Regulatory setbacks and limited financial resources are things to watch out for.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Oculis Holding AG Website
  • SEC Filings
  • Analyst Reports
  • Industry News

Disclaimers:

The information provided is for informational purposes only and should not be construed as investment advice. The financial data and analysis are based on publicly available information and may be subject to change. Investments in biopharmaceutical companies are inherently risky and may result in loss of capital.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Oculis Holding AG Ordinary shares

Exchange NASDAQ
Headquaters -
IPO Launch date 2023-03-02
CEO & Director Dr. Riad Sherif M.B.A., M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 49
Full time employees 49

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.